Myricetin

Biological Activity

Myricetin is an irreversible TrxR inhibitor (IC₅₀ = 0.62 μM). Exhibits concentration-, time- and NADH-dependent TrxR inhibition. Results in the oxidation of Trx and reduced TrxR activity in vitro in addition to the accumulation of cells in sub-G₁ phase. Reduces neoplastic transformation and induces cell death in cancer cell lines. Chemotherapeutic. Myricetin binds to the CAG motif of the mutant RNA from the HTT gene in Huntington's disease (HD). It prevents the translation of mutant huntingtin protein as well as sequestration of MBNL1. Myricetin alleviates proteotoxicity of expanded polyglutamine proteins in Cos-7 cells. Myricetin also improves neurobehavioral deficits in the HD mouse model.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity.
   Lu et al.
   Cancer.Res., 2006;66:4410
2. Selenoproteins.
   Lu & Holmgren et al.
   J.Biol.Chem., 2009;284:723
3. Mitochondrial-dependent, reactive oxygen species-independent apoptosis by myricetin: roles of protein kinase C, cytochrome c, and caspase cascade.
   Ko et al.
   Biochem.Pharmacol., 2005;69:913
4. Molecular mechanisms underlying anticancer effects of myricetin.
   Devi et al.
   Life.Sci., 2015;142:19
5. Biological effects of myricetin.
   Ong & Khoo et al.
   Gen.Pharmacol., 1997;29:121

Product Datasheets